regulatory
confidence high
sentiment positive
materiality 0.75
FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume
Nurix Therapeutics, Inc.
- FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.
- Enrollment reinitiated in Phase 1a/1b for relapsed/refractory B-cell malignancies.
- Prioritizing aggressive NHL (DLBCL, MCL) where durable complete responses previously observed.
- Patients currently enrolled and deriving benefit from prior process may continue treatment.
- Company cites accelerated interest from ASH data and Science publication on BTK degrader programs.